Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2006-5-17
pubmed:abstractText
Prevention of inhalational anthrax after Bacillus anthracis spore exposure requires a prolonged course of antibiotic prophylaxis. In response to the 2001 anthrax attack in the United States, approximately 10,000 people were offered 60 days of antibiotic prophylaxis to prevent inhalational anthrax, but adherence to this regimen was poor. We sought to determine whether a short course of antibiotic prophylaxis after exposure could protect non-human primates from a high-dose spore challenge if vaccination was combined with antibiotics. Two groups of 10 rhesus macaques were exposed to approximately 1,600 LD50 of spores by aerosol. Both groups were given ciprofloxacin by orogastric tube twice daily for 14 days, beginning 1-2 h after exposure. One group also received three doses of the licensed human anthrax vaccine (anthrax vaccine adsorbed) after exposure. In the ciprofloxacin-only group, four of nine monkeys (44%) survived the challenge. In contrast, all 10 monkeys that received 14 days of antibiotic plus anthrax vaccine adsorbed survived (P = 0.011). Thus postexposure vaccination enhanced the protection afforded by 14 days of antibiotic prophylaxis alone and completely protected animals against inhalational anthrax. These data provide evidence that postexposure vaccination can shorten the duration of antibiotic prophylaxis required to protect against inhalational anthrax and may impact public health management of a bioterrorism event.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
16
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7813-6
pubmed:dateRevised
2010-9-16
pubmed:meshHeading
pubmed-meshheading:16672361-Administration, Inhalation, pubmed-meshheading:16672361-Animals, pubmed-meshheading:16672361-Anthrax, pubmed-meshheading:16672361-Anthrax Vaccines, pubmed-meshheading:16672361-Anti-Bacterial Agents, pubmed-meshheading:16672361-Antibiotic Prophylaxis, pubmed-meshheading:16672361-Bacillus anthracis, pubmed-meshheading:16672361-Bioterrorism, pubmed-meshheading:16672361-Ciprofloxacin, pubmed-meshheading:16672361-Drug Synergism, pubmed-meshheading:16672361-Humans, pubmed-meshheading:16672361-Macaca mulatta, pubmed-meshheading:16672361-Microbial Sensitivity Tests, pubmed-meshheading:16672361-Random Allocation, pubmed-meshheading:16672361-Spores, Bacterial, pubmed-meshheading:16672361-Survival Rate, pubmed-meshheading:16672361-Time Factors, pubmed-meshheading:16672361-Vaccination
pubmed:year
2006
pubmed:articleTitle
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
pubmed:affiliation
Division of Bacteriology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural